English | 简体中文 | 繁體中文 | 한국어 | 日本語
 Multimedia Press Releases
全球領先的生活時尚和文化平台 Hypebeast 計劃通過與 Iron Spark I Inc. 合併在納斯達克上市
全球領先的生活時尚和文化平台 Hypebeast 計劃通過與 Iron Spark I Inc. 合併在納斯達克上市
April 4 2022, 10:54 HKT
more details
Hypebeast, a Leading Global Platform in Contemporary Lifestyle and Culture, Plans to List on NASDAQ through Merger with Iron Spark I Inc.
Hypebeast, a Leading Global Platform in Contemporary Lifestyle and Culture, Plans to List on NASDAQ through Merger with Iron Spark I Inc.
April 4 2022, 10:53 HKT
more details
Eunice Wong and Eleven Crypto Communities Enter Sekuya Multiverse
Eunice Wong and Eleven Crypto Communities Enter Sekuya Multiverse
April 4 2022, 10:00 HKT
more details
沛嘉醫療總收入增長253.2% 双引擎推进商業化
沛嘉醫療總收入增長253.2%  双引擎推进商業化
April 3 2022, 20:43 HKT
more details
沛嘉醫療總收入增長253.2% 双引擎推进商業化
沛嘉醫療總收入增長253.2%  双引擎推进商業化
April 3 2022, 20:43 HKT
more details
沛嘉醫療總收入增長253.2% 双引擎推进商業化
沛嘉醫療總收入增長253.2%  双引擎推进商業化
April 3 2022, 20:43 HKT
more details
沛嘉醫療總收入增長253.2% 双引擎推进商業化
沛嘉醫療總收入增長253.2%  双引擎推进商業化
April 3 2022, 20:43 HKT
more details
沛嘉醫療總收入增長253.2% 双引擎推进商業化
沛嘉醫療總收入增長253.2%  双引擎推进商業化
April 3 2022, 20:43 HKT
more details
Eunice Wong 和 11 個加密社區進入 Sekuya Multiverse
Eunice Wong 和 11 個加密社區進入 Sekuya Multiverse
April 4 2022, 07:00 HKT
more details
Eunice Wong 和 11 个加密社区进入 Sekuya Multiverse
Eunice Wong 和 11 个加密社区进入 Sekuya Multiverse
April 4 2022, 07:00 HKT
more details
沛嘉医疗公布2021年全年业绩
沛嘉医疗公布2021年全年业绩
April 2 2022, 21:41 HKT
more details
沛嘉医疗公布2021年全年业绩
沛嘉医疗公布2021年全年业绩
April 2 2022, 21:41 HKT
more details
沛嘉医疗公布2021年全年业绩
沛嘉医疗公布2021年全年业绩
April 2 2022, 21:41 HKT
more details
沛嘉医疗公布2021年全年业绩
沛嘉医疗公布2021年全年业绩
April 2 2022, 21:41 HKT
more details
沛嘉医疗公布2021年全年业绩
沛嘉医疗公布2021年全年业绩
April 2 2022, 21:41 HKT
more details
沛嘉醫療公佈2021年全年業績
沛嘉醫療公佈2021年全年業績
April 2 2022, 21:40 HKT
more details
沛嘉醫療公佈2021年全年業績
沛嘉醫療公佈2021年全年業績
April 2 2022, 21:40 HKT
more details
沛嘉醫療公佈2021年全年業績
沛嘉醫療公佈2021年全年業績
April 2 2022, 21:40 HKT
more details
沛嘉醫療公佈2021年全年業績
沛嘉醫療公佈2021年全年業績
April 2 2022, 21:40 HKT
more details
沛嘉醫療公佈2021年全年業績
沛嘉醫療公佈2021年全年業績
April 2 2022, 21:40 HKT
more details
아방스 클리니컬, 멜버른에 신규 사업소 개설 발표
아방스 클리니컬, 멜버른에 신규 사업소 개설 발표
April 2 2022, 06:00 HKT
more details
Resintech Bhd Proposes Bonus Share and Warrant Issues
Resintech Bhd Proposes Bonus Share and Warrant Issues
April 1 2022, 19:00 HKT
more details
Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology
Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology
April 1 2022, 17:47 HKT
more details
Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology
Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology
April 1 2022, 17:47 HKT
more details
Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology
Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology
April 1 2022, 17:47 HKT
more details
Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology
Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology
April 1 2022, 17:47 HKT
more details
Brawijaya Student Start-up makes Forbes 30 Under 30 List
Brawijaya Student Start-up makes Forbes 30 Under 30 List
April 4 2022, 07:00 HKT
more details
Brawijaya Student Start-up makes Forbes 30 Under 30 List
Brawijaya Student Start-up makes Forbes 30 Under 30 List
April 4 2022, 07:00 HKT
more details
經濟效益穩步提升 中再集團實現“十四五”高品質發展良好開局
經濟效益穩步提升 中再集團實現“十四五”高品質發展良好開局
April 1 2022, 15:07 HKT
more details
2022년에 Polkadot (DOT)에 대해 알아야 할 사항
2022년에 Polkadot (DOT)에 대해 알아야 할 사항
April 1 2022, 14:00 HKT
more details
 ACN Search:
 
TrustCSI 3.0 Navigates the 'Belt and Road' and Empowers Global Enterprise's Digital Journey
 
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575